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Monocytes in humans consist of 3 subsets; CD14+CD16− (classical),
CD14+CD16+ (intermediate) and CD14dimCD16+ (non-classical), which exhibit
distinct and heterogeneous responses to activation. During acute inflammation
CD14+CD16− monocytes are significantly elevated and migrate to the sites of injury
via the adhesion cascade. The field of immunometabolism has begun to elucidate
the importance of the engagement of specific metabolic pathways in immune cell
function. Yet, little is known about monocyte metabolism and the role of metabolism
in mediating monocyte activation and adherence to vessels. Accordingly, we aimed to
determine whether manipulating the metabolism of CD14+CD16− monocytes alters
their ability to become activated and adhere. We discovered that LPS stimulation
increased the rate of glycolysis in human CD14+CD16− monocytes. Inhibition of
glycolysis with 2-deoxy-D-glucose blunted LPS-induced activation and adhesion
of monocytes. Mechanistically, we found that increased glycolysis was regulated
by mTOR-induced glucose transporter (GLUT)-1. Furthermore, enhanced glycolysis
increased accumulation of reactive oxygen species (ROS) and activation of p38 MAPK,
which lead to activation and adhesion of monocytes. These findings reveal that glycolytic
metabolism is critical for the activation of CD14+CD16− monocytes and contributes
to our understanding of the interplay between metabolic substrate preference and
immune cell function.
Keywords: glycolysis, monocytes, inflammation, metabolism, adhesion
INTRODUCTION
Innate immune cells such as monocytes play an essential role during inflammation. Monocytes
emerge from the bone marrow or spleen into the blood when inflammatory cues are released
from sites of injury and ultimately migrate from the blood into the inflamed tissue. This
is commonly referred to as the leukocyte adhesion cascade (1). This is a stepwise process
initially involving the activation of monocytes, allowing them to roll and tether roll and tether
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along the activated endothelium followed by firm adhesion and
extravasation into inflamed sites. These events are necessary
for the survival of the host, as inflammation is important
for clearing invading pathogens and repairing damaged tissues
(2). On the other hand, excessive inflammation can lead to
detrimental effects, resulting in further damage to tissues, and
the development of chronic inflammatory diseases such as
atherosclerosis and other auto-inflammatory disorders (3–5).
Therefore, understanding the underlying mechanisms that
regulate monocyte adhesion can provide information on how
to manipulate the cell’s ability to adhere during acute or
chronic inflammation.
It has become increasingly appreciated that the metabolic
status of a cell can dictate its functional phenotype. We and
others have shown that stimulating cells with inflammatory
stimuli switches the energy profile of macrophages and T
cells, i.e., from using mitochondrial oxidative phosphorylation
(OXPHOS) to glycolysis (6–8). Changes in the cellular substrates
and metabolic preferences under resting and activated states
has sparked investigations into further understanding immune
cell metabolism (i.e., immunometabolism) in relation to their
function. It has become increasingly evident that manipulating
metabolic pathways influences the development and function of
cells. For example, inhibiting glycolysis in LPS-stimulated bone
marrow-derived macrophages (BMDMs), prevents the release of
the inflammatory cytokine interleukin (IL)-1β (9).
In humans, blood monocytes consist of 3 functionally
distinct subsets, CD14+CD16− (classical), CD14+CD16+
(intermediate), and CD14dimCD16− (non-classical) (10).
CD14+CD16− monocytes represent 85% of the circulating
monocyte population whereas the other two subsets each make
up ∼5–8% of the population. In mice, however, monocytes
consist of only two subsets, Ly6-Chi and Ly6-Clo. Ly6-Chi
monocytes are considered to be inflammatory and have been
likened to the CD14+CD16− monocyte population in humans.
During acute inflammation, such as a bacterial infection,
these are the subsets that respond first. Therefore, in this
study we aimed to investigate how human CD14+CD16−
monocytes metabolically respond to inflammatory stimuli such
as lipopolysaccharide (LPS) and how manipulating monocyte
metabolism could alter their functional responses, particularly in
relation to their activation and ability to undergo firm adhesion.
MATERIALS AND METHODS
Isolation of Peripheral Blood Mononuclear
Cells From Human Buffy Coats
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy coats of healthy volunteers supplied by the Australian
Red Cross Blood Service via density-centrifugation using Ficoll-
Paque solution (density= 1.77). Ethics was obtained through the
Alfred Hospital human ethics committee.
CD14+CD16− Monocyte Isolation From
PBMCs
PBMCs were resuspended using PBS without Ca2+ and Mg2+
containing 2mM EDTA and 5% FBS (FACS buffer) and labeled
with a cocktail of fluorescent markers (1:400) consisting of
Lin (PE—CD2, PE—CD15, PE—CD56, PE—Nkp46, PE−19),
APC—HLA-DR, PB—CD14, PE/Cy7—CD16. After 30min of
incubation on ice, they were then washed and Lin−HLA-
DR+CD14+CD16− monocytes were collected via FACS using
the BD Aria 1 (Biosciences) at the AMREP Flow cytometry
core facility.
Stimulation/Inhibition of Cells
PBMCs (for flow cytometry assays) and isolated CD14+CD16−
monocytes were stimulated with lipopolysaccharides (LPS)
(100 ng/ml) for 1 h in the presence or absence of 1 h of
metabolic inhibitor pre-treatment; glycolysis inhibitor: 2-Deoxy-
D Glucose (2DG) (5mM), mechanistic target of rapamycin
(mTOR) inhibitor: rapamycin (20 nM), reactive oxygen species
(ROS) inhibitor: NAC (1mM), p38 MAPK inhibitor: SB-203580
(5 nM) and mitochondrial ROS scavenger: MitoQ (100 nM).
Flow Cytometry
PBMCs were resuspended in 200 µl of FACs buffer. A cocktail
of the fluorophores (1:400) were added to stain for the different
monocyte subsets. These consisted of Lin (PE—CD2, PE—
CD15, PE—CD56, PE—Nkp46, PE−19), APC—HLA-DR, PB—
CD14, PE/Cy7—CD16. To measure CD11b levels or GLUT-
1 expression, FITC- CD11b (1:400), and FITC—GLUT-1 was
also added, respectively. After incubating on ice for 30min,
they were then washed and transferred into FACS tubes. In
order to measure metabolism of cells via flow cytometry, 10 nM
MitoTracker Deep Red, 4µM 2-NBDG, 5µM MitoSOX, and
10µM H2DCFDA were stained in RPMI 1640 and incubated
in 37◦C for 20min before they were washed and transferred
into FACS tubes. Cells were immediately run on the BD LSRII
Fortessa (BD Biosciences). 100,000 cells were collected for
analysis. Unstained and single stained controls were used to set
up voltages to compensate for spectral overlap. Flow cytometry
data were quantified using FlowJo vX0.7 (FlowJo LCC) software.
Seahorse Bioanalyser Assay
Monocytes were pre-treated with inhibitors and seeded at
100,000 cells/well in the XFe 96 well cell culture microplate
(Agilent Technologies). The microplate was spun at 1,000 RPM
for 5min at 4◦C; acc = 5, dec = 0 to obtain a monolayer of
monocytes in each well. The supernatant was discarded and
175 µl of seahorse media [XF based minimal DMEM (Agilent
Technologies) supplemented with 5.5mM Glucose Solution
(Gibco), 1mM Sodium Pyruvate (Gibco) and 2mML-Glutamine
(Gibco)], containing the same concentrations of inhibitors, were
carefully added so as not to disturb the cell layer. The XFe 96
well cell culture microplate was incubated at 37◦C in a non-
CO2 incubator for at least 30min. The assay cartridge was
hydrated overnight with 200 µl of XF Calibrant Media (Agilent
Technologies) at 37◦C (in non-CO2 incubator) before LPS was
suspended in 25 µl of seahorse media and was added to Port
A of the assay cartridge at a concentration of 100 ng/ml. Basal
extracellular acidification rate (ECAR) was measured for 4 ×
6.5min cycles. LPS was automatically injected into the XFe cell
culture plate after the 4th cycle and ECAR readings were recorded
for 1 h post-LPS injection.
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Vessel Chamber Adhesion Assay
Aortic vessels were isolated from C57BL/6 mice and stimulated
in Krebs buffer with bovine serum albumin (BSA) (1:1,000
w/v) and TNF-α for 4 h at 37◦C. TNF-α activated vessels were
mounted onto the cannulas and Krebs solution warmed at
37◦C was used to flood the vessel chamber to mimic in-vivo
conditions. Monocytes were re-suspended in 6ml of RPMI
at the concentration of 1 × 106 cells/ml. 1mM of Vybrant
Dil (Invitrogen) was added for 10min in dark conditions, to
fluorescently label the cells. Cell solutions were transferred into
a terafusion syringe pump (Teruma) which was used to direct
the movement of the cells through the aortic vessel at a rate
of 7.1ml per hour. Images of adhered monocytes were taken
using the Zesiss Discover V.20 Fluorescence Microscope (Carl
Zeiss MicroImaging) mounted on a Hammastsu HD Camera
(Hamamatsu R©) at 0, 2.5, 5, 7.5, and 10min. Data was then
quantified by calculating the number of stationary fluorescent
dots per field of view (FOV).
F-Actin Assay
Eight well chamber slides (Lab-Tek) were pre-coated with 200
µl/well of fibrinogen (100µg/ml) and incubated overnight at
4◦C. The next day, each well was washed twice with PBS
without Mg2+ and Ca2+ to get rid of non-adhered fibrinogen
via aspiration. Two-hundred microliter of 3% BSA were then
added and incubated at room temperature for 15 minutes
before washing again with PBS twice. Two-hundred microliter
of monocytes (at 1 × 106/ml in RPMI 1640 media) were then
added into each well and stimulated with 100 ng/ml LPS for 1 h at
37◦C. Cells were then washed with PBS twice to remove unbound
monocytes. Two-hundred microliter of 4% para-formaldehyde
(PFA) was then added for 15min at room temperature to fix
adhered monocytes onto slides. Again, PBS was used to wash off
the PFA before permeabilising cells with 0.1% Triton X-100 for
10min at room temperature. After washing cells with PBS, 200
µl of PBS containing 10% FBS was used to block any non-specific
binding for 15min at room temperature. Cells were washed
again before staining with fluorescent markers of F-actin (33 nM
phalloidin) and nucleus (1 ng/ml 4′,6-diamidino-2-phenylindole
(DAPI) for 20min in the dark at room temperature. Cells were
then washed twice with PBS and the gasket were removed. slides
were finally allowed to completely dry before mounting on No.
2 glass coverslips (Menzel) using Dako fluorescence mounting
media. Imaging was performed through the monash micro
imaging core, on a Nikon A1r confocal microscope using NIS-
elements software (Nikon) at 60X magnification. To quantify
F-actin staining, the fluorescence intensity of phalloidin stain
per cell, normalized to cell size, was measured using Image J.
Moreover, cells were counted individually, using the Image J
count function, to quantify the number of adherent monocytes.
Western Blot
Protein samples were isolated from lysed Monocytes. A 10%
SDS-PAGE gel was used to separate the protein samples which
were subsequently transferred onto a nitrocellulose membrane.
Five percent fat-free skim milk in tris-buffered saline with
tween (TBST) was used to block the membrane for non-
specific binding and washed with before the addition of various
primary antibodies (1:1,000) consisting of p-mTOR (Santa Cruz),
p-ERK1/2 (Cell Signaling Technologies), β-actin (Cell Signaling
Technologies), p-p38 MAPK (Cell Signaling Technologies), p38
MAPK (Cell Signaling Technologies), and HSP90 (Cell Signaling
Technologies). Membranes were then incubated overnight at
4◦C. Appropriate secondary antibodies (1:2,000) were added
for 1 h at room temperature and subsequently washed before
visualization of the protein bands using enhanced chemi-
luminescence reagents (PerkinElmer) and quantified using
Quantity One (Bio-Rad) software.
Statistical Analyses
Data are presented as mean± SEM where each individual donor
was denoted by n. P values were calculated by using unpaired
Student’s t-test or one-way ANOVA followed by Tukey’s post-hoc
test using Graphpad Prism 7 (Graphpad Software). P-values of
<0.05 were deemed to be statistically significant.
RESULTS
LPS Activation Increases Glycolysis in
Human CD14+CD16− Monocytes
It is becoming increasingly appreciated that immune cells alter
their metabolism when they become activated (11, 12). To
determine the metabolic preference of human CD14+CD16−
monocytes after activation with LPS, we isolated cells from
buffy coats of healthy volunteers via fluorescence-activated cell
sorting (FACS) before placing them in the seahorse XFe 96
bioanalyser to characterize their metabolic preference. We noted
a significant increase in extracellular acidification rate (ECAR)
within 20min of LPS stimulation (Figures 1A,B) indicating
increased rate of glycolysis. This was also associated with
enhanced glucose uptake, measured via flow cytometry using 2-
NBDG (Figure 1C). Moreover, we found no significant change
in oxygen consumption rate (OCR), which is a proxy of oxidative
phosphorylation (OXPHOS), in CD14+CD16− monocytes after
LPS stimulation (Figures 1D,E). We also used flow cytometry to
quantify mitochondrial activity, which confirmed our findings
from the seahorse bioanalyser (Figure 1F). These data suggest
that stimulating monocytes with LPS causes an increase in
glycolysis while not affecting OXPHOS.
Inhibiting Glycolysis Decreases Monocyte
Activation and Adhesion
Given that we found CD14+CD16− monocytes increase
glycolysis following LPS stimulation, we aimed to determine
how important glucose utilization was to their ability to
activate in response to LPS. To do this we used 2-Deoxy-D-
glucose (2-DG), a glucose analog that enters into the cell like
glucose but inhibits the first step of glycolysis via competitively
blocking hexokinase, a rate limiting step of glycolysis (13). As
expected, pre-treating cells with 2-DG reduced the increase
in glycolysis caused by LPS (Figures 2A,B). Additionally, pre-
treating cells with 2-DG significantly inhibited the activation of
the CD14+CD16− monocytes as determined by the cell surface
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FIGURE 1 | LPS increases glycolysis in human CD14+CD16− monocytes. Isolated human CD14+CD16− monocytes were treated with or without 100 ng/ml LPS.
A seahorse bioanalyser was used to measure extracellular acidification rate (ECAR) (A,B); n = 4. Flow cytometry was used to measure glucose uptake using
fluorescent analog 2-NBDG (C); n = 6. A seahorse bioanalyser was used to measure oxygen consumption rate (OCR) (D,E); n = 4. Mitochondrial activity was
measured using flow cytometry (F); n = 7. Data are mean ± SEM (un-paired t-test: *p < 0.05, ***p < 0.001).
activation marker CD11b (Figure 2C). To functionally confirm
the role of glycolysis in LPS-induced monocyte adhesion, we
performed a static adhesion assay where we pre-coated wells with
fibrinogen which allows activated monocytes to bind via CD11b.
Monocyte adhesion was assessed using confocal microscopy
where cells were also stained to quantify F-actin content as
another measure of cell activation. As expected, following LPS
stimulation, there was a significant increase in the number of
monocytes adhering to fibrinogen as well as an increase in F-
actin content. These effects were blunted when cells were pre-
treated with 2-DG (Figures 2D–F). Furthermore, we performed
a shear flow cell adhesion assay to monitor in real-timemonocyte
adhesion under shear stress in TNF-α activated mouse aorta
ex vivo. We treated CD14+CD16− human monocytes with LPS
1 h before flowing the cells through the endothelium and found
that there was a significant increase in monocyte adhesion. This
increase in monocyte adhesion was abolished when pre-treating
with 2-DG (Figures 2G–I). This confirms our hypothesis that
blocking glycolysis prevents LPS-induced monocyte activation
and adhesion.
mTOR Is Involved in Regulating Glycolysis
in LPS-Induced Monocytes
To understand the mechanisms by which LPS increases
glycolysis, we explored the mTOR pathway as it has been known
to be involved in regulating glycolysis (14). Following LPS
treatment we found a significant increase in the phosphorylation
of mTOR in the CD14+CD16− monocytes and using
rapamycin as a positive control for mTOR phosphorylation,
phosphorylation of mTOR was significantly reduced as expected
(Figure 3A). The activation of mTOR is also known to further
upregulate glucose transporter (GLUT)-1 to the cell surface
in order to facilitate increased glucose uptake (15). When we
measured GLUT-1 expression using flow cytometry, we found
that LPS significantly increased cell surface GLUT-1 levels.
When we inhibited mTOR activity using rapamycin, GLUT-1
expression was significantly blunted in LPS-induced monocytes
(Figure 3B). This suggests that the increase in cell surface
GLUT-1 is regulated by mTOR in monocytes. Furthermore, we
also showed that inhibiting mTOR significantly prevented the
increase in LPS-stimulated glycolysis (Figures 3C,D), suggesting
mTOR is a master regulator of glycolysis in CD14+CD16−
monocytes. Next, we blocked mTOR to determine whether
this affected the activation and adhesion of monocytes. When
we pre-treated cells with rapamycin, we were able to prevent
CD11b expression in LPS-induced monocytes (Figure 3E). The
anti-inflammatory effects of mTOR blockade were also seen in
the static adhesion assay where pre-treating cells with rapamycin
prevented the number of monocytes adhered to fibrinogen. In
addition, we found a decrease in F-actin content (Figures 3F–H).
This suggests that the mTOR pathway is involved in LPS-
induced activation and adhesion of CD14+CD16− monocytes
by controlling glucose uptake and glycolysis.
Blocking p-38 MAPK Signaling Prevents
LPS-Induced Activation and Adhesion
To further understand the signaling pathways mediating
the activation and adhesion of LPS-stimulated monocytes,
we measured mitogen-activated protein kinases (MAPKs),
extracellular signal-related kinases (ERKs) and p38 MAPK,
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FIGURE 2 | Glycolysis is required for LPS-induced monocyte activation and adhesion. Isolated human CD14+CD16− monocytes were pre-treated with or without
5mM 2-DG for 1 h followed by 1 h of 100 ng/ml LPS stimulation. Seahorse bioanalyser was used to measure extracellular acidification rate (ECAR) (A,B); n = 4. Flow
cytometry was used to measure CD11b expression (C); n = 6–8. Representative images (20µm scale bar) (D) of the number of adhered monocytes (E) and F-actin
content measured via confocal microscopy (F); n = 3–5. Representative image of shear flow adhesion assay (white dots = adhered cells) (G). Quantification over
10min time course (H) and at 10min (I); n = 3–5. Data are mean ± SEM (one-way ANOVA with Tukey’s test: *&∧p < 0.05, **&p < 0.01, ***p < 0.0001). In (H),
∧ denotes comparison between LPS vs. 2DG-LPS.
which are known to be activated during inflammation (16–18).
As expected, both MAPKs were significantly phosphorylated
when monocytes were treated with LPS (Figures 4A,B).
Interestingly, blocking glycolysis using 2-DG did not prevent
the phosphorylation of ERK1/2 (Figure 4A). Moreover, when
we pre-treated cells with rapamycin and 2-DG, p38 MAPK
phosphorylation was significantly decreased (Figure 4B).
Therefore, we decided to inhibit p38 MAPK to determine
whether this affected LPS-induced monocyte activation and
adhesion. We employed SB-203580, an inhibitor of p38 MAPK,
which confirmed that this pathway was involved in monocyte
activation as we noted LPS was no longer able to increase
the cell surface expression of CD11b (Figure 4C). Consistent
with the inability of LPS to induce CD11b, we also found a
reduction in the number of monocytes adhering to fibrinogen
when p38 MAPK was inhibited (Figures 4D,E). To further
confirm p38 MAPK occurs downstream of mTOR and glycolysis,
we measured mTOR phosphorylation via western blot and
also GLUT-1 levels via flow cytometry with SB-203580 in the
presence of LPS and confirmed that phosphorylation of mTOR
and GLUT-1 levels were unchanged (Figures 4F,G). These
data suggest that LPS-mediated glycolysis and mTOR signaling
induce p38 MAPK to promote CD14+CD16− monocyte
activation and adhesion.
Reactive Oxygen Species Are Involved in
Glycolysis-Mediated Activation and
Adhesion
Next, we aimed to mechanistically link glycolysis with the
induction of p38 MAPK signaling in driving CD14+CD16−
monocyte activation and adhesion. Inflammatory signaling can
trigger p38 MAPK activation by ROS and preventing ROS
accumulation using anti-oxidants averts p38 MAPK activation
(16, 19, 20). Since one of the by-products of glycolysis is ROS
generation, we hypothesized that this may be the link between
glycolysis and p38 MAPK activation. Indeed, we found that LPS
increased ROS accumulation in monocytes via flow cytometry
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FIGURE 3 | mTOR pathway is involved in regulating glycolysis in LPS-induced monocytes. Isolated human CD14+CD16− monocytes were pre-treated with or
without 20 nM rapamycin an hour before 1 h 100 ng/ml LPS stimulation. mTOR phosphorylation was quantified by western blot at 30min after LPS stimulation (A); n =
6–7. Flow cytometry was used to measure GLUT-1 expression; n = 3–5 (B). Extracellular acidification rate (ECAR) was measured in real-time (C,D); n = 3–4. CD11b
expression was measured by flow cytometry (E); n = 6–7. Static cell adhesion assay performed utilizing F-actin and DAPI stain via confocal microscopy (20µm scale
bar) (F–H); n = 3–4. Data are mean ± SEM (un-paired t-test and one-way ANOVA with Tukey’s test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
(Figure 5A). Our data suggest that ROS generation was a
consequence of increased glycolysis, as interventions upstream of
glycolysis, rapamycin, and 2-DG, were able to block global ROS
levels using the H2DCFDA fluorescent indicator (Figure 5A).
Moreover, to determine whether the increase in ROS production
was generated from glycolysis and not glucose utilization via
the mitochondria, we specifically stained for mitochondrial ROS
using MitoSOX, which we found to be unchanged with LPS
(Figure 5B). To confirm that mitochondrial ROS did not play a
role during acute LPS activation, we treated cells with MitoQ that
specifically reduces mitochondrial ROS and showed that global
ROS levels (Figure 5C) and CD11b expression were unchanged
(Figure 5D). We also measured ROS production in LPS-induced
monocytes that were pre-treated with the p38 MAPK inhibitor
SB-203580 and found no change in ROS, suggesting that p38
MAPK is downstream of ROS in LPS-activated monocytes
(Figure 5E). Next, we inhibited ROS oxidation of cysteines using
N-acetyl-L-cysteine (NAC) and measured phosphorylation of
p38 MAPK to delineate whether ROS activated p38 MAPK.
Indeed, we found that pre-treating cells with NAC before
incubating with LPS prevented p38 MAPK activation but
not ERK1/2 phosphorylation, suggesting that the ROS driven
pathway was specific to p38 MAPK signaling (Figures 5F,G).
These results show that ROS production in LPS-induced
monocytes occurs downstream of the mTOR and glycolytic
pathway but upstream of p38 MAPK. More importantly,
inhibiting ROS production using NAC, significantly prevented
LPS-induced CD11b expression (Figure 5H). Furthermore, NAC
was able to affect LPS-induced monocyte adhesion as well as
reduce F-actin formation (Figures 5I–K). These results indicate
that LPS stimulation of monocytes triggers mTOR regulated
glycolysis, which drives ROS, causing downstream p38 MAPK
activation, resulting in monocyte activation and adhesion.
DISCUSSION
During an acute inflammatory response, monocytes become
activated, adhere to the endothelium, and transmigrate into
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FIGURE 4 | p38 MAPK is involved in LPS-induced monocyte activation and adhesion. ERK1/2 phosphorylation were measured with or without 5mM 2-DG followed
by 1 h of 100 ng/ml LPS stimulation (A); n = 4–5. p38 MAPK phosphorylation was measured with or without 5mM 2-DG or 20 nM rapamycin before 100 ng/ml LPS
stimulation (B); n = 6–7. Cells were pre-treated with 5 nM SB-203580 followed by 1 h of 100 ng/ml LPS stimulation before measuring CD11b expression via flow
cytometry (C); n = 8. Static cell adhesion assay was performed utilizing F-actin and DAPI stain via confocal microscopy (20µm scale bar); n = 3–4 (D–E). mTOR
phosphorylation was quantified by western blot at 30min after LPS stimulation in the presence of 5 nM SB-203580 (F); n = 3. Flow cytometry was used to measure
GLUT-1 expression; n = 3–4 (G). Data are mean ± SEM (one-way ANOVA with Tukey’s test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
the inflamed tissue. However, the mechanistic pathways by
which human CD14+CD16− monocytes activate and adhere,
in particular the specific metabolic pathways are yet to be
fully elucidated. In this study, we revealed that increased
flux through glycolysis is critical to induce the signaling
pathways that monocytes rely on for adherence. We found
that LPS-stimulated human CD14+CD16− monocytes increase
CD11b expression and adhesion via the phosphorylation of
mTOR which facilitates the uptake of glucose and glycolysis.
When we further investigated the mechanistic link between
glycolysis and adhesion, we found that an increase in
glycolysis resulted in the production of ROS which activated
the p38 MAPK pathway, leading to monocyte activation
and adhesion.
Glycolysis and oxidative phosphorylation (OXPHOS) via the
mitochondria are the two main metabolic pathways, which
can control the overall phenotype of the cell. A classic
example of this are the metabolic status of inflammatory
and anti-inflammatory macrophages. Inflammatory or M1-like
macrophages are highly glycolytic, while anti-inflammatory or
M2-like macrophages have been found to be mitochondrial
dependent, using both glucose and fatty acids for OXPHOS
(11, 12). More importantly, when glycolysis or OXPHOS are
inhibited using specific metabolic inhibitors it reduces the ability
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FIGURE 5 | ROS regulates p38 MAPK-induced monocyte activation and adhesion. Isolated human CD14+CD16− monocytes were pre-treated with or without
20 nM rapamycin or 5mM 2-DG followed by 1 h of 100 ng/ml LPS stimulation before H2DCFDA (A) and MitoSOX (B) levels were measured via flow cytometry;
n= 4–8. Cells were pre-treated with 100 nM MitoQ followed by 1 h of 100 ng/ml LPS stimulation before H2DCFDA (C) and CD11b (D) levels were measured via flow
cytometry; n = 7–8. Cells were pre-treated with 5 nM SB-203580 followed by 1 h of 100 ng/ml LPS stimulation before measuring H2DCFDA levels via flow cytometry
(E); n = 4. Cells were pre-treated with or without 1mM NAC before stimulating with 100 ng/ml LPS for 30min before measuring ERK1/2 (F) and p38 MAPK (G)
phosphorylation; n = 4–5. CD11b expression was measured via flow cytometry; n = 6–8 (H); n = 6–7. Static cell adhesion assay performed utilizing F-actin and DAPI
stain via confocal microscopy (20µm scale bar) (I–K); n = 3–6. Schematic diagram of proposed mechanistic pathway of acute LPS-induced CD14+CD16+
monocyte activation and adhesion (L). Data are mean ± SEM (one-way ANOVA with Tukey’s test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
of macrophages to become inflammatory or anti-inflammatory,
respectively. Here, we demonstrate a similar scenario in human
CD14+CD16− monocytes where LPS increased glucose uptake
and glycolysis. This is consistent with findings from Stienstra’s
group who also show an increase in glycolysis with LPS (21).
However, it was somewhat surprising OXPHOS ormitochondrial
activity was not reduced in the presence of LPS. This could
suggest that the mitochondria does not play an essential role
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in providing the increase in energy metabolism for cellular
activation in human CD14+CD16− monocytes during short
(1 h) exposure compared to 24 h of LPS stimulation, where
many other cellular changes are likely to be occurring (21).
The non-reliance on the mitochondria in acute responses
could be because CD14+CD16− monocytes do not require
much energy as they are carried around the body by the
circulatory system and require rapid activation upon an
inflammatory stimulus and so have evolved to require little
respirative metabolism. Thus, consistent with the hypothesis
that CD14+CD16− monocytes use glycolytic metabolism, when
this pathway was inhibited using 2-DG, we found a loss in
the ability of these monocytes to increase cell surface CD11b
and to adhere. This builds on a growing body of evidence
that the cellular metabolic preference is a key determinate of
cellular function.
Previously, it has been noted that mTOR is involved
in regulating cell adhesion in cancer cells; however, the
mechanistic pathway downstream of mTOR has not been
explored. mTOR, the central regulator of cellular growth and
proliferation, also governs glycolysis. Studies in BMDMs have
shown that mTOR is responsible for upregulating glucose
transporters, namely GLUT-1 (15). Glucose transporters are
involved in facilitating the uptake of glucose which increases
the rate of glycolysis. This pathway was also activated in our
human CD14+CD16− monocytes as inhibition of mTOR with
rapamycin prevented GLUT-1 movement to the surface as well
as glycolysis, leading to a reduction in monocytic activation
and adhesion.
Delving further into the mechanisms linking glycolysis to
the activation and adhesion of LPS-induced monocytes, LPS has
previously been known to stimulate many activation pathways
including p38 MAPK and ERK1/2 in human CD14+CD16−
monocytes. Additionally, p38 MAPK and ERK1/2 have been
shown to regulate adhesion of tumor-associated macrophages,
suggesting their involvement is important in cellular activation
in order to cause adhesion to vessels or a matrix (16, 18).
Interestingly, only p38 MAPK was found to be important
in glycolysis-mediated cell adhesion in the CD14+CD16−
monocytes, suggesting that glycolytic events are key in regulating
the phosphorylation of p38 MAPK. One of the stressors that
is capable of signaling via p38 MAPK is ROS. Within the
glycolytic pathway, we found that non-mitochondrial generated
ROS appeared to activate p38 MAPK in order to cause LPS-
induced monocyte activation. The source of non-mitochondrial
ROS is likely to be NADPH-oxidase (NOX)-dependent, which
is induced via the glycolytic pathway (22). Additionally, studies
have shown that NOX enzymes are increased in human
monocytes and macrophages upon inflammatory conditions in
addition with increased ROS levels (23).
Clinical trials testing the benefits of antioxidants in
CVD-related clinical trials have been disappointing, with
many larger clinical trials showing no beneficial effects when
given antioxidants such as vitamin E, C or coenzyme Q.
After careful reflection on these trials, the limitations of
these studies should be considered before closing the door
to the therapeutic potential of antioxidants in CVD. These
include dosage, efficacy, in vivo biological activity, specificity
and statistical power (24–26). However, the importance of
ROS in cellular metabolism in CVD is regaining traction.
Importantly, we are now gaining a better understanding
on the regulator of cellular ROS and how to harness the
power of endogenous antioxidant pathways such as Nrf2
or restoring mitochondrial health (if the mitochondria is
the driver) (27). Another important point to consider is the
timing of intervention to therapeutic gain, perhaps anti-
oxidants need to be administered earlier in life as opposed
to testing this in middle to older aged participants in trial
setting and formulating appropriate primary endpoints.
How glycolysis regulates p38 MAPK is currently unknown,
but given p38 MAPK is downstream of ROS, it is likely
that MKK3/6, and potentially ASK1, are intermediary
targets (19, 28). Nonetheless, LPS-induced glycolysis is
required for the phosphorylation of p38 MAPK to cause
monocyte activation.
In summary, we have found that the metabolism of
glucose by human CD14+CD16− monocytes in response to
LPS is critical for the activation of these cells (Figure 5L).
These findings contribute to a larger body of evidence
revealing that changes in cellular metabolism are central
for the cell to respond to extrinsic stimuli (bacterial,
viral, cytokines, etc). These metabolic changes assist the
cell in performing effector functions and as such have
become a key interest in disrupting unwanted processes,
particularly in the immune system. Understanding these
pathways and selectively inhibiting glycolysis may aid in
chronic diseases where excessive monocyte recruitment
is detrimental.
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